0.3991
price down icon1.51%   -0.0061
after-market アフターアワーズ: .41 0.0109 +2.73%
loading
前日終値:
$0.4052
開ける:
$0.42
24時間の取引高:
1.52M
Relative Volume:
0.98
時価総額:
$19.16M
収益:
-
当期純損益:
$-37.65M
株価収益率:
-0.239
EPS:
-1.67
ネットキャッシュフロー:
$-24.14M
1週間 パフォーマンス:
+2.02%
1か月 パフォーマンス:
-40.79%
6か月 パフォーマンス:
-77.45%
1年 パフォーマンス:
-63.05%
1日の値動き範囲:
Value
$0.3922
$0.42
1週間の範囲:
Value
$0.38
$0.4488
52週間の値動き範囲:
Value
$0.30
$4.28

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Name
名前
Reviva Pharmaceuticals Holdings Inc
Name
セクター
Healthcare (1163)
Name
電話
(408) 501-8881
Name
住所
10080 N WOLFE ROAD, CUPERTINO
Name
職員
14
Name
Twitter
Name
次回の収益日
2025-03-31
Name
最新のSEC提出書
Name
RVPH's Discussions on Twitter

RVPH を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RVPH
Reviva Pharmaceuticals Holdings Inc
0.3991 26.60M 0 -37.65M -24.14M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.81 120.40B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
542.52 61.30B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.53 41.06B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
564.59 34.29B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.55 27.09B 3.81B -644.79M -669.77M -6.24

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-09-20 開始されました ROTH MKM Buy
2023-06-08 開始されました The Benchmark Company Speculative Buy
2022-01-24 開始されました H.C. Wainwright Buy

Reviva Pharmaceuticals Holdings Inc (RVPH) 最新ニュース

pulisher
Jul 20, 2025

Is Reviva Pharmaceuticals Holdings Inc. a good long term investmentRapid profit acceleration - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock priceOutstanding risk-reward balance - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

Is Reviva Pharmaceuticals Holdings Inc. Equity Warrant a good long term investmentMassive stock growth - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Reviva Pharmaceuticals Holdings Inc. stockRapid market gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Reviva Pharmaceuticals Holdings Inc. Stock Analysis and ForecastStrongest growth potential - Autocar Professional

Jul 19, 2025
pulisher
Jul 19, 2025

What drives Reviva Pharmaceuticals Holdings Inc. stock priceUnmatched profit potential - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Can Reviva Pharmaceuticals Holdings Inc. stock recover from recent declineControlled Risk High Reward Plan - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Reviva Pharmaceuticals Holdings Inc. Equity Warrant Stock Analysis and ForecastLightning-fast capital gains - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

How Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock performs during market volatilityWealth Building Stock Portfolio - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

Why Reviva Pharmaceuticals Holdings Inc. stock attracts strong analyst attentionFree Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock price move sharplyFree Stock Market Entry & Exit Signals - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Reviva Pharmaceuticals Holdings Inc. stock price move sharplyCapital Doubling Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Reviva Pharmaceuticals Holdings Inc: Analyzing RVPH Stock Trends - investchronicle.com

Jul 15, 2025
pulisher
Jul 15, 2025

Why Reviva Pharmaceuticals Holdings Inc. Equity Warrant stock attracts strong analyst attentionSmall Risk Large Return Trades - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Reviva Pharmaceuticals Holdings Inc. stock performs during market volatilityReal Time Stock Signal - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Brokerages - Defense World

Jul 05, 2025
pulisher
Jun 28, 2025

Reviva Pharmaceuticals’ (RVPH) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Jun 28, 2025
pulisher
Jun 27, 2025

Reviva Pharmaceuticals Makes A $10 Million Stock Offering Move - Finimize

Jun 27, 2025
pulisher
Jun 27, 2025

Reviva Pharmaceuticals (RVPH) Maintains Buy Rating and Price Tar - GuruFocus

Jun 27, 2025
pulisher
Jun 26, 2025

Reviva Pharmaceuticals (RVPH) Launches $10M Public Offering - GuruFocus

Jun 26, 2025
pulisher
Jun 26, 2025

Dow Surges 200 Points; US GDP Contracts 0.5% - Benzinga

Jun 26, 2025
pulisher
Jun 25, 2025

Reviva Pharmaceuticals (RVPH) Announces Public Offering of Commo - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Reviva Pharmaceuticals (RVPH) Declines After Announcing Public Offering - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Reviva Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria

Jun 25, 2025
pulisher
Jun 10, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Buy” by Brokerages - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Ameriprise Financial Inc. Takes $84,000 Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

RVPH: Open Label Extension Results & Key Opinion Leader Discussion - MSN

Jun 06, 2025
pulisher
Jun 05, 2025

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Late-Stage CNS Drug Developer Reviva Pharma Reveals New Pipeline Updates at Major Neuroscience Conference - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Data Readout Positive from Trial of New Schizophrenia Drug - streetwisereports.com

Jun 04, 2025
pulisher
Jun 04, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives Buy Rating from D. Boral Capital - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Reviva Pharmaceuticals (RVPH) Receives Buy Rating from D. Boral - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - MarketScreener

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva reports positive year-long schizophrenia drug study - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus

Jun 02, 2025

Reviva Pharmaceuticals Holdings Inc (RVPH) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.88
price down icon 0.59%
$35.59
price up icon 0.34%
$102.56
price down icon 1.55%
$26.20
price down icon 5.18%
$110.02
price down icon 0.92%
biotechnology ONC
$294.55
price up icon 1.45%
大文字化:     |  ボリューム (24 時間):